openRxiv
Cure8 research brief
Why This Matters
Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.
Who Should Pay Attention
Researchers studying IBD biomarkers and transcriptomics, clinicians managing UC patients considering anti-TNF withdrawal, and patients on anti-TNF biologics interested in treatment cessation risks.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used mucosal rectal biopsies and RNA sequencing from patients in a randomized withdrawal trial (BIOSTOP) and trained a semi-supervised ML model on a targeted 38-gene panel.
The model reported good sensitivity for detecting patients who later relapsed after anti-TNF withdrawal but showed only moderate specificity, and performance dropped in the independent inference cohort.
The authors highlight several genes (including IL1B, TYROBP, S100A8, TNF) that contributed most to relapse prediction and others (MUC2, HMGCS2, CDKN1A) associated with sustained remission.
The paper is a preprint and reports promising early results, but the authors and the abstract note the need for multi-center validation in larger, more diverse cohorts before clinical use.
Keep In Mind
The study is a preprint (medRxiv) using samples from the BIOSTOP randomized withdrawal trial. Performance was better in the primary test cohort than in the inference cohort; authors call for multi-center validation before clinical deployment.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationopenRxiv
AuthorsGhita Bouhddi, Emma Rapp, Piotr Artiemjew +7 more
Study typePosted Content
Indexed viaCrossref
Source typeResearch paper
PublishedOct 7, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: South-Eastern Norway Health Authority, award 2023090
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Biopsy-Based Molecular Signatures Predicting Therapeutic Response in Ulcerative Colitis
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
Response-aware molecular subtyping of ulcerative colitis for patient stratification via interpretable machine learning.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Cytokine biomarkers for response to IL23 p19 inhibition for inflammatory bowel diseases
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...